[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100474974":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":18,"responsibleParty":36,"collaborators":39,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":7,"eligibilityCriteria":87,"healthyVolunteers":84,"sex":88,"minAge":89,"maxAge":7,"enrollmentInfo":90,"targetDuration":7,"studyType":93,"phases":7,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"First Affiliated Hospital, Sun Yat-Sen University","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Xinhua Zhang, PhD","First affiliated hosptial,Sun Yat-sen university","PRINCIPAL_INVESTIGATOR",[14],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","+8620-87332200","zhangxinhua@mail.sysu.edu.cn",[19],{"facility":20,"status":21,"city":22,"state":7,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"The First Affiliated Hospital, Sun Yat-sen University","RECRUITING","Guangzhou","510080","China","CN",{"type":27,"coordinates":28},"Point",[29,30],113.25,23.11667,{"lat":30,"lon":29},[33],{"name":34,"role":15,"phone":35,"phoneExt":7,"email":17},"Xinhua Zhang","+8613828463644",{"type":37,"investigatorFullName":38,"investigatorTitle":5,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Xinhua Zhang, MD",[40,42,44,46,48,50,52,54,56,58,60,62,64,66,68,70,72,74,76,78,80],{"name":41,"class":6},"Peking University Cancer Hospital & Institute",{"name":43,"class":6},"Fudan University",{"name":45,"class":6},"Peking University People's Hospital",{"name":47,"class":6},"Chinese PLA General Hospital",{"name":49,"class":6},"Xiangya Hospital of Central South University",{"name":51,"class":6},"Peking University Shenzhen Hospital",{"name":53,"class":6},"Nanfang Hospital, Southern Medical University",{"name":55,"class":6},"West China Hospital",{"name":57,"class":6},"Jiangsu Cancer Institute & Hospital",{"name":59,"class":6},"Shanghai Zhongshan Hospital",{"name":61,"class":6},"Sun Yat-Sen University Cancer Center",{"name":63,"class":6},"Xijing Hospital",{"name":65,"class":6},"Shengjing Hospital",{"name":67,"class":6},"Shanghai Jiao Tong University School of Medicine",{"name":69,"class":6},"Liaoning Cancer Hospital & Institute",{"name":71,"class":6},"Sixth Affiliated Hospital, Sun Yat-sen University",{"name":73,"class":6},"Fujian Medical University Union Hospital",{"name":75,"class":6},"Cancer Hospital of Guangxi Medical University",{"name":77,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"name":79,"class":6},"First Affiliated Hospital of Chongqing Medical University",{"name":81,"class":6},"Chongqing University Cancer Hospital","100474974","a-multicenter-study-of-avapritinib-efficacy-and-safety-of-metastatic-or-unresectable-gastrointestinal-stromal-tumors-100474974",false,"NCT05464875","A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors","Inclusion Criteria:\n\n* Patients who are aged ≥ 18 years.\n* Gastrointestinal stromal tumors confirmed by histopathological examination, and CD- and\u002For DOG-1-positive by immunohistochemistry.\n* Presence of mRECIST v1.1-compliant lesions with at least one measurable lesion (non-lymphadenopathy ≥1.0 cm or ≥2-fold scan slice thickness).\n* Treatment with Avapritinib.\n* Patients with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2 at screening.\n* Patient informed consent and signed written consent form.\n* The patient was compliant and voluntarily scheduled for follow-up, treatment, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* KIT or PDGFRA wild type.\n* Failure to complete continuous atorvastatin for at least 15 days due to intolerability or disease progression.\n* Other serious acute or chronic physical or mental problems, or laboratory abnormalities, may increase the risk associated with participation in the study or use of drugs, or interfere with the judgment of the study results and, in the judgment of the investigator, are not considered appropriate for participation in the investigator.","ALL","18 Years",{"count":91,"type":92},74,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter, observational real-world study to explore the therapy patterns and clinical outcomes of Avapritinib in patients with metastatic or unresectable gastrointestinal stromal tumors.",[96,97,98],"Gastrointestinal Stromal Tumors","Unresectable Solid Tumor","Recurrent Metastatic Malignant Neoplasm",[100,101],"Avapritinib","Genetic testing","2025-02-24",{"date":104,"type":105},"2025-02-26","ACTUAL",{"date":107,"type":105},"2022-07-09",{"date":109,"type":92},"2025-12-31",{"name":38,"class":6},1]